Olio Labs
Olio Labs is an AI-powered tool that focuses on developing combinatorial therapeutics for challenging diseases. Unlike traditional approach...
Last verified:
What is Olio Labs?
Olio Labs is an AI-driven biotechnology company that designs combination therapeutics for the world's toughest diseases, with a current focus on obesity and metabolic disorders. Rather than targeting one or two proteins like traditional drugs, Olio Labs uses machine learning and systems biology to model how thousands of interacting proteins behave across organs, enabling the discovery of multi-agent treatment combinations that are more effective and have fewer side effects.
The company’s core product is a computational platform that performs rapid in silico testing of trillions of possible drug combinations to identify only the most promising candidates for further development. This platform integrates custom-built machine learning models trained on real-world biological data with systems pharmacology and network modeling, allowing Olio Labs to simulate how combinations will behave in different tissues and demographic groups before moving to wet-lab experiments or clinical studies.
Olio Labs is primarily for pharmaceutical companies, biotech startups, academic research institutions, and investors interested in next-generation drug discovery approaches. Its technology is especially valuable for developing treatments for complex, multifactorial diseases where single-target drugs have limited efficacy or unacceptable side effect profiles. The company also collaborates with academic institutions and runs preclinical studies to validate its lead combinations.
Key target areas include obesity, where Olio Labs claims its lead combinations outperform current market-leading GLP-1 drugs like Ozempic in animal models, as well as other conditions with strong multi-pathology involvement. The platform is designed to be extended to multiple disease indications, with the long-term goal of automating large parts of the drug discovery and development pipeline.
Overall, Olio Labs positions itself as a full-stack AI drug discovery company: from protein-level modeling and combination design to in silico optimization, preclinical validation, and eventual clinical collaboration. Its approach aims to dramatically reduce the cost and time of discovering effective therapies while improving safety and efficacy through better targeting of the right biological pathways in the right tissues.
Olio Labs pricing
Pricing model: Free
Olio Labs does not offer a public free tier or self-serve pricing. Access to the platform is by business or research collaboration only, typically arranged through direct contact with the founders or sales team ([email protected] or [email protected]). The company is venture-backed and sells its capabilities as a drug discovery service and/or platform licensing to pharmaceutical companies, biotech firms, and academic institutions. Specific plan names, monthly fees, and subscription tiers are not published on the website.
Olio Labs pros
- AI-driven design of combination therapeutics
- Models thousands of interacting proteins, not just 1–2 targets
- Rapid in silico testing of trillions of combinations
- Custom machine learning built on real biological data
- Systems biology and network modeling integration
- Focus on reducing side effects via better tissue targeting
- Lead obesity combinations outperform Ozempic in preclinical models
- Demonstrated 4x acceleration of discovery process
- Reported 90% cost reduction in early discovery
- Sex-aware modeling showing different responses in men vs women
- Collaborations with academic institutions and Y Combinator backing
- Platform designed to extend to multiple disease indications
- Full-stack approach from modeling to preclinical validation
- Automates large parts of traditional drug discovery workflow
- Potential to repurpose existing drugs via new combinations
Olio Labs cons
- No publicly available free tier or consumer product
- Platform is not exposed as a standalone software tool
- Limited public detail on exact algorithms and data sources
- Results so far mostly from preclinical and animal models
- Clinical trials and human data not yet widely published
- Target audience is specialized (pharma/biotech/research)
- Pricing and licensing terms are not transparent
- Requires significant domain expertise to interpret outputs
Frequently asked questions about Olio Labs
What does Olio Labs do?
Olio Labs uses artificial intelligence and systems biology to design combination therapeutics for complex diseases. Instead of targeting one or two proteins like traditional drugs, the company models how thousands of interacting proteins behave across the body, then uses machine learning to search trillions of possible drug combinations and identify those that are more effective with fewer side effects.
How is Olio Labs different from regular drug discovery?
Traditional drug discovery focuses on single-target or dual-target therapies optimized through years of trial and error. Olio Labs instead uses a computational platform to rapidly test trillions of multi-agent combinations in silico, leveraging systems pharmacology and network modeling to predict how combinations will work in different tissues and patient groups before moving to experiments.
What diseases is Olio Labs targeting first?
Olio Labs’ current lead programs focus on obesity and metabolic disease, with combinations designed to outperform GLP-1 drugs like Ozempic in preclinical models. The platform is intentionally general and is being expanded to multiple other indications where single-target drugs have limited efficacy or high side effects.
Does Olio Labs sell software or a service?
Olio Labs operates as a full-stack AI drug discovery company rather than selling a standalone SaaS product. It provides its capabilities as a service and/or platform license to pharmaceutical companies, biotech firms, and research institutions, often in the form of collaborative development programs and preclinical studies.
Is there a free tier or trial for Olio Labs?
No. Olio Labs does not offer a public free tier, self-serve trial, or consumer-facing product. Access is by invitation or business collaboration only, typically arranged via direct email to the founders or sales team.
What kind of data does Olio Labs use to train its models?
The company trains custom machine learning models on real-world biological and experimental data, including protein interaction networks, pathway information, and preclinical results. This data is integrated with systems biology and network pharmacology models to simulate how drug combinations affect different tissues and patient populations.
Has Olio Labs published clinical results?
As of now, Olio Labs has primarily published preclinical and mechanistic findings, including animal model results and sex-based difference studies in GLP-1 drug responses. Large-scale human clinical trial data is not yet widely available in public literature.
Who can use Olio Labs’ platform?
The platform is designed for pharmaceutical companies, biotech startups, academic research institutions, and investors focused on advanced drug discovery. It is not intended for individual patients or general consumers.
How does Olio Labs handle sex differences in drug response?
Olio Labs explicitly models sex-based differences in protein expression and drug effects. For example, its research has identified that women may have higher GLP-1 receptor expression in brain regions linked to nausea, helping explain why women experience more severe side effects from drugs like Ozempic. This insight is incorporated into combination design to improve tolerability.
How can I collaborate with or invest in Olio Labs?
Collaborations and investment inquiries are handled directly through the company’s founders and business team. Interested parties can contact [email protected] or [email protected]. The company is venture-backed, with funding from Y Combinator, ZAKA Ventures, Pioneer Fund, Overwater Ventures, and others.